Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 11—November 2003
Research

Hantavirus Pulmonary Syndrome, Southern Chile

Raúl Riquelme*Comments to Author , Mauricio Riquelme*, Antoni Torres†, Maria Luisa Rioseco*, José Antonio Vergara*, Luis Scholz‡, and Andrea Carriel*
Author affiliations: *Puerto Montt Regional Hospital, Puerto Montt, Chile; †Clinical Institute of Pneumology and Thoracic Surgery Hospital Cliníc, Barcelona, Spain; ‡Osorno Regional Hospital, Osorno, Chile

Main Article

Table 4

Variables with statically significant differences in survivors versus no survivors with hantavirus pulmonary syndromea

Survivors
No survivors
Mean + SD CI 95% Mean + SD CI 95% p
APACHE 7.1 + 1.2 4.4 to 9.8 21 + 8.3 8.3 to 15.0 0.0000
PAFI 211 + 127 134 to 288 95 + 78 39.5 to 151.3 0.0097
Blood pH 7.43 + 0.04 7.40 to 7.45 7.32 + 0.12 7.23 to 7.41 0.0043
Creatinine (mg/dL) 1.08 + 0.23 0.94 to 1.23 1.8 + 0.59 1.35 to 2.27 0.0003
Prothrombin (%) 90.9 + 17.8 75.9 to 105.7 63.2 + 32.0 23.4 to 102.9 0.0340
SBP (mm Hg) 103.7 + 20.0 92.6 to 114.8 76.6 + 47.3 42.7 to 110.4 0.0296
Respiratory rate 25.2 + 10.2 19.5 to 30.8 38.4 + 7.8 32.4 to 44.4 0.0015
Pulse 104.6 + 16.5 95.4 to 113.8 117.7 + 21.9 102 to 133.4 0.0512

aSD, standard deviation; CI, confidence interval; PAFI, arterial oxygen tension/inspiratory oxygen fraction; SBP, standard blood pressure.

Main Article

Page created: April 20, 2012
Page updated: April 20, 2012
Page reviewed: April 20, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external